Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort

The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for more than one year.

Marketing to the Science

At Mohr Marketing, we use this data as the foundation of our acquisition strategy. We don’t cast a wide, generic net. Instead, our funnels are mathematically aligned with the BMJ findings.

Our Three-Layer Defense System

1. Cumulative Dose Verification: We verify the “1-Year Rule,” ensuring the plaintiff’s usage meets the high-risk threshold identified in the science.
2. Exclusion Logic: We actively filter out unrelated neurological conditions such as glioblastomas or general migraines without a tumor diagnosis.
3. Fraud Scrub: We utilize advanced Scammer Scrub™ technology to flag bot traffic and duplicate submissions in real-time.

Your Lead Generation Partner

In an era of increasing scrutiny, your firm needs an audit-ready docket. Mohr Marketing provides the medical data integrity and regulatory compliance necessary to build a defensible, high-value Depo-Provera inventory.

Ready to fill your docket with valid cases?

Partner with Mohr Marketing to secure high-quality, compliant plaintiffs.

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Read Press Release

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Mohr Marketing Team

Summary

Article Name

Depo-Provera MDL Science-Back Intake: How We Filter for the "5.6x Risk" Cohort

Description

The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn't just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for more than one year.

Author

Mohr Marketing Team

Publisher Name

Mohr Marketing, LLC

Publisher Logo